SCHEMBL6846450

SCHEMBL6846450

Nc1nc(Sc2cccc(O)c2)c2ncn(CCOCP(=O)(O)O)c2n1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
POLB P06746 4/20 0.44
PNP P00491 5/20 0.43
POLA1 P09884 1/20 0.41
POLG P54098 1/20 0.41
CYP2C19 P33261 2/20 0.39
HPRT1 P00492 2/20 0.38
SLC29A1 Q99808 1/20 0.37
CYP1A2 P05177 2/20 0.37
HK1 P19367 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
HIF1A Q16665 1/20 0.36
PHLPP2 Q6ZVD8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7127274 0.90 FGFR1 (0.53) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL6846424 0.90 FGFR1 (0.53) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL7121312 0.89 FGFR1 (0.47) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL7126838 0.88 FGFR1 (0.46) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL7125992 0.87 FGFR1 (0.46) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL6846396 0.87 SLC22A6 (0.39) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL7128849 0.86 FGFR1 (0.45) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL7125887 0.86 FGFR1 (0.45) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL6840927 0.86 POLB (0.41) FGFR1SLC22A6POLBPNPPOLA1
SCHEMBL7130456 0.86 FGFR1 (0.44) FGFR1SLC22A6POLBPNPPOLA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6767900-B2 VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES MITSUBISHI PHARMA CORPORATION (JP) 2004-07-27 US claimed
US-20030153534-A1 Phosphonate nucleotide compound MITSUBISHI PHARMA CORPORATION (JP) 2003-08-14 US claimed
US-20030109498-A1 Antiviral agent for drug-resistant virus MITSUBISHI PHARMA CORPORATION (JP) 2003-06-12 US claimed
US-6767900-B2 VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES MITSUBISHI PHARMA CORPORATION (JP) 2004-07-27 US disclosed
US-20030153534-A1 Phosphonate nucleotide compound MITSUBISHI PHARMA CORPORATION (JP) 2003-08-14 US disclosed
US-20030109498-A1 Antiviral agent for drug-resistant virus MITSUBISHI PHARMA CORPORATION (JP) 2003-06-12 US disclosed
WO-2003028737-A1 ANTI-VIRAL AGENTS AND IN-VITRO METHOD FOR THE IDENTIFICATION OF CANDIDATES ABLE TO INHIBIT BINDING OF POLYMERASE TO EPSILON MITSUBISHI PHARMA CORPORATION (JP) 2003-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109498-A1 Antiviral agent for drug-resistant virus TPMT, MTAP, TYMP FGFR1 1401/4885SLC22A6 399/4885POLB 462/4885
US-20030153534-A1 Phosphonate nucleotide compound TYMP, PNP, MTAP FGFR1 903/4885SLC22A6 451/4885POLB 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.